Reason for request
Inclusion on the lists of medicines reimbursed by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of this proprietary drug is substantial. |
Clinical Added Value
| no clinical added value |
The Transparency Committee considers that 3rd generation VARNOLINE CONTINU does not provide an improvement in actual benefit (IAB V) compared to 2nd generation oral contraceptives. |
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
0dQEWC6ZY08LjfAa
